Summary of the News
The latest research, published in the top journal *New England Journal of Medicine*, presents the one-year follow-up data from the Phase I clinical trials of the world’s first lipid-lowering gene editing therapy, CTX310. After just one injection for patients with refractory hyperlipidemia, there was no need to take any additional lipid-lowering medications. After one year, the key lipid indicators decreased by an average of nearly 50%, and the effect remained stable. The ultimate goal of the developing company is to achieve a “one-shot treatment that solves the problem for life.” Currently, the same CRISPR technology is also being used in trials for “one-shot treatment of hypertension,” indicating that this once-exclusively expensive gene editing technology is beginning to be applied to common chronic diseases like hyperlipidemia and hypertension, which affect hundreds of millions of people. This could revolutionize the approach to chronic disease management. However, this therapy is still far from being available to the general public, as there are many unresolved issues regarding safety, cost, and suitability.
Detailed Analysis
1. How Does This “One-Shot, Lifelong Solution” for Lipid Reduction Work?
Many people wonder why previous lipid-lowering drugs only worked for half a year to a year, while this new drug claims to provide lifelong relief. The difference lies in the mechanism: Previous drugs, such as statins or the recently approved long-acting injections that require two injections per year, work by providing external assistance to the body’s lipid-clearing abilities. These treatments need to be repeated regularly because the body’s natural lipid-clearing mechanisms are insufficient.
CTX310, on the other hand, directly alters the body’s genetic makeup by cutting out a gene called ANGPTL3. This gene, which was beneficial in ancient times when food was scarce, slows down the body’s lipid-clearing process, helping the body store fat for survival during times of famine. However, in modern times, with an abundance of food, this gene becomes a burden, leading to higher lipid levels. By cutting out this gene, the body’s natural lipid-clearing ability is permanently enhanced, eliminating the root cause of hyperlipidemia and eliminating the need for ongoing medication.
The published trial data supports this mechanism: In the highest-dose group, patients experienced an average 52.5% reduction in bad cholesterol and 47.8% reduction in triglycerides after one year of treatment; some patients with extremely high lipid levels even saw reductions of over 80%. Patients who previously required multiple medications to achieve normal lipid levels saw their indicators meet the standard after just three months of treatment.
2. It Solves a Long-Persistent Problem Frustrating Doctors Worldwide
In China, there are 330 million people with cardiovascular diseases, and 40% of adults have abnormal lipid levels, with 300 million people having elevated lipid levels. The issue is not a lack of lipid-lowering drugs—ranging from inexpensive statins to expensive long-acting injections, a combination of these treatments can almost bring all hyperlipidemia patients to normal levels. The real challenge is patient non-compliance: Data shows that half of American patients with hyperlipidemia stop taking their medication within a year, even those who have had heart attacks. The situation in China is even worse, with many people thinking they don’t need medication if they don’t experience symptoms. This “one-shot, lifelong” therapy potentially solves the problem of patients forgetting, not wanting, or finding medication troublesome to take.
3. But This Therapy Is Still Far from Being Available to the General Public
Many online promotional accounts claim that hyperlipidemia will no longer require medication in the future, which is misleading. This therapy is unlikely to be available to the general public for at least 10 years:
- Safety: Gene editing is irreversible, and any mistakes or unknown side effects cannot be reversed. The trials have only lasted for one year, and it’s unclear what long-term effects cutting out this gene might have.
- Cost: The only approved gene editing therapy for a similar condition currently costs $2.2 million (about 15 million RMB). Even if costs decrease with mass production, the initial price will still be too high for most people.
- Target Population: This therapy would only be used for extremely critical patients who have tried all other treatments without success and are at high risk of heart attacks. It would not be practical for the general population, which can control their lipid levels with inexpensive statins.
4. A Trendsetter for the Medical Industry
CTX310 marks a significant milestone for the biopharmaceutical industry, opening up new opportunities in the trillion-dollar chronic disease market. While it’s initially aimed at rare diseases, its potential impact is much broader. With millions of patients affected by hyperlipidemia, hypertension, diabetes, and gout, the potential market size is enormous. The same CRISPR technology is being tested for hypertension, and more gene editing therapies for common chronic diseases are expected to emerge in the next few years, shifting the approach from lifelong daily medication to one-shot, long-term or even lifelong cures.
5. For the General Public, the Most Reliable Solution Remains Lifestyle Changes
For people with high lipid levels, it’s important to remember that even if this new therapy becomes more affordable, it won’t solve the problem if you continue to eat unhealthy foods. Effective, cost-free, and side-effect-free methods of lowering lipid levels include a low-fat diet, exercise, and avoiding late nights. These are far more reliable than any unproven “miracle drugs.”